Quigley's QR-435 shows antiviral activity against herpes during preclinical studies

By Angela McDaniels

Seattle, Feb. 13 - The Quigley Corp. said that subsidiary Quigley Pharma's QR-435 demonstrated antiviral activity against ocular and genital herpes in preclinical studies.

Quigley is negotiating with the university in which the studies took place to begin further trials.

The studies were designed to determine the in vitro inhibitory activity of QR-435 against two ocular isolates of herpes simplex virus-1 and two non-ocular isolates of herpes simplex virus-2.

Quigley is a natural health medical science company based in Doylestown, Pa.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.